322 OLIVE OILS AND HEALTH PROSPECTIVE OBSERVATIONAL STUDIES (See EPIDEMIOLOGICAL STUDIES) PROSTAGLANDINS (See EICOSANOIDS) PROTHROMBOTIC ENVIRONMENT (See THROMBOSIS) RANDOMISED (RANDOMISED (See in EPIDEMIOLOGICAL STUDIES / Randomised Trials) RANDOMISED CONTROLLED STUDIES (See EPIDEMIOLOGICAL STUDIES / Randomised trials) RANDOMISED INTERVENTION STUDY (See EPIDEMIOLOGICAL STUDIES / Randomised trials) RANDOMISED STUDY/IES (See EPIDEMIOLOGICAL STUDIES / Randomised trials) RANDOMISED TRIALS (See EPIDEMIOLOGICAL STUDIES) REACTIVE SPECIES (See OXIDATIVE STRESS) REGENERON Regeneron is a cocktail of two pharmaceutical drugs (casirivimab and imdevimab) developed by the company of the same name for the treatment of COVID-19, the disease caused by the SARS-CoV-2 coronavirus. Both casirivimab and imdevimab are monoclonal antibodies (lab-made antibodies produced using biotechnological techniques to target a specific infection, in this case SARS-CoV-2) and are administered directly to patients through intravenous infusion. This monoclonal antibody treatment gained public attention when it was used on a former President of the United States during his illness. These antibodies are a treatment, not a vaccine. Vaccines do not treat disease; instead, they work by activating the body’s natural immune response to help prevent certain infections. There is some preliminary evidence suggesting that monoclonal antibody therapy may reduce the amount of SARS-CoV-2 (viral load) in the body. However, some studies have reported that its efficacy is limited or only moderate. However, the “Human Medicines Committee” of the “European Medicines Agency” (EMA) has concluded that this combination may be used to treat COVID-19 in patients at risk of developing severe illness. The “World Health Organization” (WHO) has also recommended this treatment. REMDESIVIR (See CoViD-19 DISEASE)
RkJQdWJsaXNoZXIy Njg1MjYx